Neuralstem, Inc. (CUR)
-NYSE MKT 1.49 
0.04(2.76%) May 17, 4:00PM EDT
| Prev Close: | 1.45 |
|---|
| Open: | 1.52 |
|---|
| Bid: | 1.49 x 1400 |
|---|
| Ask: | 1.55 x 600 |
|---|
| 1y Target Est: | 2.13 |
|---|
| Beta: | 1.29 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 1.40 - 1.59 |
|---|
| 52wk Range: | 0.42 - 1.96 |
|---|
| Volume: | 2,133,474 |
|---|
| Avg Vol (3m): | 412,054 |
|---|
| Market Cap: | 102.51M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.18 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NEURALSTEM, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- Smaller Companies With Potential For Big Returnsat Seeking Alpha(Thu, May 16)
- Neuralstem: Update On ALS Trial Could Be A Catalyst For The Stockat Seeking Alpha(Thu, May 16)
- Neuralstem CEO, Richard Garr, To Present At Annual World Stem Cells And Regenerative Medicine Congress In LondonPR Newswire(Thu, May 16)
- Neuralstem Rounding Second With Phase II ALS Trialat Seeking Alpha(Thu, May 16)
- Neuralstem Principal Investigator, Dr. Eva Feldman, Presents Phase I ALS Trial Data At The Romanian Neurological Society CongressPR Newswire(Mon, May 13)
- SmithOnStocks Opines On Recent Biotech Newsat Seeking Alpha(Mon, May 13)
- Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical UpdatePR Newswire(Fri, May 10)
- NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Fri, May 10)
- NEURALSTEM, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- 5 Stocks Under $10 Set to Soarat TheStreet(Thu, May 9)
- NEURALSTEM, INC. Files SEC form 8-K, Regulation FD Disclosure, Other EventsEDGAR Online(Wed, May 8)
- Neuralstem ALS Trial Investigator And Patient On Sirius XMPR Newswire(Wed, May 8)
- Neuralstem: Anticipating More Efficacy Data From ALS Trial And Update On New Clinical Trialsat Seeking Alpha(Tue, May 7)
- StemCells Inc: CEO Martin McGlynn Is Building A Blockbuster Companyat Seeking Alpha(Thu, May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 281.83 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.18 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.05 |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Neuralstem, Inc., a biopharmaceutical company, focuses on the development and commercialization of treatments for central nervous system disease based on human neural stem cells and the use of small molecule compounds.
View More